Gsa Capital Partners LLP Savara Inc Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$1.91 - $4.08 $52,041 - $111,167	-27,247 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$0.71 - $4.91 $22,312 - $154,301	-31,426 Reduced 53.56%	27,247 $122,000
Q3 2019 Nov 12, 2019	SELL	$2.16 - $3.2 $60,944 - $90,288	-28,215 Reduced 32.47%	58,673 $155,000
Q2 2019 Aug 06, 2019	BUY	$2.37 - $11.7 $205,924 - $1.02 Million	86,888 New	86,888 $206,000
Q3 2018 Nov 13, 2018	SELL	$10.49 - $12.87 $417,334 - $512,020	-39,784 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$8.55 - $13.76 $215,460 - $346,752	25,200 Added 172.79%	39,784 $450,000
Q1 2018 May 11, 2018	BUY	$8.99 - $14.95 $131,110 - $218,030	14,584 New	14,584 $134,000

128

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $303M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.